Weitzel Jeffrey N, Blazer Kathleen R, MacDonald Deborah J, Culver Julie O, Offit Kenneth
Division of Clinical Cancer Genetics, Department of Population Sciences, City of Hope, Duarte, CA.
CA Cancer J Clin. 2011 Sep-Oct;61(5):327-59. doi: 10.3322/caac.20128. Epub 2011 Aug 19.
Scientific and technologic advances are revolutionizing our approach to genetic cancer risk assessment, cancer screening and prevention, and targeted therapy, fulfilling the promise of personalized medicine. In this monograph, we review the evolution of scientific discovery in cancer genetics and genomics, and describe current approaches, benefits, and barriers to the translation of this information to the practice of preventive medicine. Summaries of known hereditary cancer syndromes and highly penetrant genes are provided and contrasted with recently discovered genomic variants associated with modest increases in cancer risk. We describe the scope of knowledge, tools, and expertise required for the translation of complex genetic and genomic test information into clinical practice. The challenges of genomic counseling include the need for genetics and genomics professional education and multidisciplinary team training, the need for evidence-based information regarding the clinical utility of testing for genomic variants, the potential dangers posed by premature marketing of first-generation genomic profiles, and the need for new clinical models to improve access to and responsible communication of complex disease risk information. We conclude that given the experiences and lessons learned in the genetics era, the multidisciplinary model of genetic cancer risk assessment and management will serve as a solid foundation to support the integration of personalized genomic information into the practice of cancer medicine.
科技进步正在彻底改变我们对遗传性癌症风险评估、癌症筛查与预防以及靶向治疗的方法,实现个性化医疗的承诺。在这本专著中,我们回顾了癌症遗传学和基因组学领域科学发现的演变,并描述了将这些信息转化为预防医学实践的当前方法、益处和障碍。文中提供了已知遗传性癌症综合征和高 penetrance 基因的总结,并与最近发现的与癌症风险适度增加相关的基因组变异进行了对比。我们描述了将复杂的基因和基因组检测信息转化为临床实践所需的知识范围、工具和专业技能。基因组咨询面临的挑战包括需要进行遗传学和基因组学专业教育以及多学科团队培训,需要基于证据的关于检测基因组变异临床效用的信息,第一代基因组图谱过早营销带来的潜在危险,以及需要新的临床模式来改善复杂疾病风险信息的获取和负责任的沟通。我们得出结论,鉴于遗传学时代的经验和教训,遗传性癌症风险评估和管理的多学科模式将成为支持将个性化基因组信息整合到癌症医学实践中的坚实基础。